COVID-19

Azelastine, commonly used in nasal sprays to combat allergies, was found to reduce the incidence of SARS-CoV-2 among healthy controls in a phase 2 trial.

COVID-19 vaccination significantly reduces the risk of asthma and other airway inflammatory diseases, offering vital protection against respiratory complications.

The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.

Rhinovirus infection, which causes the common cold, could offer infected children more respiratory pathway protection from SARS-CoV-2 infection.

The development of multisystem inflammatory syndrome in children infected with SARS-CoV-2 was associated with more marked shifts in metabolic parameters, leading to increased cardiovascular disease risk.

Individuals who have survived childhood cancer had a higher risk of developing a severe COVID-19 infection, while exhibiting a lower risk of contracting the virus.

Designed for use in Celiac disease, larazotide was found to hasten resolution of multisystem inflammatory syndrome symptoms in children with the condition.

Secretary Robert F. Kennedy Jr announced the cancellation of 22 mRNA vaccine technology investments, alleging the vaccines lacked effectiveness against respiratory diseases.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

A large retrospective study funded by the CDC indicates broad additional protection against COVID-19, especially for older adults and immunocompromised patients.

Receiving a COVID-19 vaccination vastly reduced the risk of long-term hospitalization, necessitating dialysis, and morbidity in patients hospitalized with acute kidney injury related to SARS-CoV-2 infection.

mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.

The lawsuit alleges that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. violated the law when issuing new guidance for COVID-19 vaccination.

Lung transplant recipients were found to be at heightened risk of developing secondary lung infections, including bacterial and fungal infections, due to unique risk factors.

When infected with SARS-CoV-2, the virus that causes COVID-19, higher levels of proinflammatory cytokines are released in men compared with women, leading to more severe disease.

Results from a systematic review shed light on the role that obesity and overweight play in increasing the severity of symptoms in long COVID.

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk factors for severe COVID-19.

The change is poised to impact countless individuals who may have sought a COVID-19 vaccine this upcoming respiratory season.

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.

In a major policy shift, officials from the FDA announced a new regulatory framework for COVID-19 vaccinations, prioritizing adults 65 years and older and individuals with serious comorbidities putting them at high risk for severe COVID-19.

COVID-19 can reshape one’s academic journey and outlook on life.

The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.